KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Operating Income: 2009-2024

Historic Operating Income for Neogenomics (NEO) over the last 16 years, with Dec 2024 value amounting to -$92.1 million.

  • Neogenomics' Operating Income fell 27.44% to -$27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$120.9 million, marking a year-over-year decrease of 30.98%. This contributed to the annual value of -$92.1 million for FY2024, which is 14.51% up from last year.
  • As of FY2024, Neogenomics' Operating Income stood at -$92.1 million, which was up 14.51% from -$107.7 million recorded in FY2023.
  • In the past 5 years, Neogenomics' Operating Income ranged from a high of -$14.0 million in FY2020 and a low of -$157.6 million during FY2022.
  • For the 3-year period, Neogenomics' Operating Income averaged around -$119.2 million, with its median value being -$107.7 million (2023).
  • Its Operating Income has fluctuated over the past 5 years, first crashed by 748.73% in 2021, then spiked by 31.65% in 2023.
  • Yearly analysis of 5 years shows Neogenomics' Operating Income stood at -$14.0 million in 2020, then tumbled by 748.73% to -$118.8 million in 2021, then plummeted by 32.73% to -$157.6 million in 2022, then surged by 31.65% to -$107.7 million in 2023, then climbed by 14.51% to -$92.1 million in 2024.